The agreement represents an important milestone as the manufacture of the vaccine cases commences
21 April 2021 - 09:32
UPDATED 21 April 2021 - 17:53
byLisa Steyn
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Emerging helium and gas producer Renergen has struck a deal with a SA logistics company for the manufacture and purchase of its new helium-powered vaccine storage cases, ahead of phase 2 of SA’s Covid-19 vaccine rollout programme, which begins in May.
DPD Laser is an express courier company that operates under the Dawn Wing brand in SA. Renergen, listed on the JSE and in Australia, is developing a natural gas and helium project in the Free State and in December 2020 announced its invention of the Cryo-Vacc — a case that keeps the vaccines ultra-cold during transportation for weeks, allowing them to travel for longer and reach remote areas.
The agreement between Renergen and DPD Laser relates to a fixed purchase of 110 Cryo-Vacc cases, in a combination of three sizes — with the largest carrying up to 2,400 vials — and will be delivered in May 2021.
While the agreement is not material to Renergen from a revenue perspective, the company said it represents a significant milestone as it commences the manufacturing of its trademarked Cryo-Vacc cases.
“Given the current uncertainty around which vaccines will be used at various vaccination points across SA, we have the ideal solution, storage and distribution,” said DPD Laser CEO Anton Visagie. “Our technology can handle all three required temperatures [for the different vaccines] of 2ºC to -8ºC, -20ºC and -70ºC without being dependent on an external power supply for periods between seven and 35 days.”
The company, whose share price has more than doubled so far in 2021, recently announced its first direct helium-supply deal with iSi Automotive.
Renergen shares were up 1.36% to R25.40 on Wednesday.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Renergen clinches first order for Cryo-Vacc cases
The agreement represents an important milestone as the manufacture of the vaccine cases commences
Emerging helium and gas producer Renergen has struck a deal with a SA logistics company for the manufacture and purchase of its new helium-powered vaccine storage cases, ahead of phase 2 of SA’s Covid-19 vaccine rollout programme, which begins in May.
DPD Laser is an express courier company that operates under the Dawn Wing brand in SA. Renergen, listed on the JSE and in Australia, is developing a natural gas and helium project in the Free State and in December 2020 announced its invention of the Cryo-Vacc — a case that keeps the vaccines ultra-cold during transportation for weeks, allowing them to travel for longer and reach remote areas.
The agreement between Renergen and DPD Laser relates to a fixed purchase of 110 Cryo-Vacc cases, in a combination of three sizes — with the largest carrying up to 2,400 vials — and will be delivered in May 2021.
While the agreement is not material to Renergen from a revenue perspective, the company said it represents a significant milestone as it commences the manufacturing of its trademarked Cryo-Vacc cases.
“Given the current uncertainty around which vaccines will be used at various vaccination points across SA, we have the ideal solution, storage and distribution,” said DPD Laser CEO Anton Visagie. “Our technology can handle all three required temperatures [for the different vaccines] of 2ºC to -8ºC, -20ºC and -70ºC without being dependent on an external power supply for periods between seven and 35 days.”
The company, whose share price has more than doubled so far in 2021, recently announced its first direct helium-supply deal with iSi Automotive.
Renergen shares were up 1.36% to R25.40 on Wednesday.
steynl@businesslive.co.za
NEVA MAKGETLA: Fragmentation of state adds to failure of vaccine rollout
J&J notes strong sales in first quarter, as it awaits word on Covid-19 vaccine
AYABONGA CAWE: Vaccination process crawls along behind the pursuit of wealth
WATCH: Stock pick — Johnson & Johnson
Companies in this Story
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Renergen names helium-supply customer to comply with ASX rules
EU regulator gives green light for J&J to resume vaccine shipments
Groups slam the state for rushing vaccine indemnity fund
Vaccine sales scams proliferate as intermediaries target European countries
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.